Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 2/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.39 |
| ▸ | LIMK1 | P53667 | 4/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | KRAS | P01116 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19169895 | 0.97 | TNKS (0.46) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL19986176 | 0.90 | TNKS (0.41) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL20226314 | 0.86 | TNKS (0.42) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL21389042 | 0.85 | TNKS (0.40) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL19169558 | 0.85 | TNKS (0.44) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL18017908 | 0.84 | MEN1 (0.44) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL18017815 | 0.84 | MEN1 (0.44) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL18017773 | 0.84 | MEN1 (0.44) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL18017898 | 0.84 | MEN1 (0.44) | TNKSTNKS2MAPTPIM1PIM2 | |
| SCHEMBL18017762 | 0.84 | MEN1 (0.44) | TNKSTNKS2MAPTPIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180155325-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE AND ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2018-06-07 | — | — | US | disclosed |
| US-20180155325-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE AND ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2018-06-07 | — | — | US | disclosed |
| US-20180083202-A1 | COMPOUND FOR ORGANIC OPTOELECTRIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRIC DEVICE AND ORGANIC OPTOELECTRIC DEVICE AND DISPLAY DEVICE | SAMSUNG SDI CO., LTD. (KR) | 2018-03-22 | — | — | US | disclosed |
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | LG CHEM, LTD. (KR) | 2017-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170213984-A1 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME | CRY1, NOS1, NOLC1 | TNKS 3525/4885TNKS2 4086/4885MAPT 1589/4885 |
| US-20180155325-A1 | COMPOUND FOR ORGANIC OPTOELECTRONIC DEVICE, COMPOSITION FOR ORGANIC OPTOELECTRONIC DEVICE AND ORGANIC OPTOELECTRONIC DEVICE AND DISPLAY DEVICE | OXER1, OCIAD1, OR10J3 | TNKS 4372/4885TNKS2 4626/4885MAPT 1820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.